It was exciting to see Dimension Bio featured in Fast Company this week — a national spotlight that underscores just how far this Chicago-born biotech has pushed the boundaries of regenerative medicine.
The profile traces the company’s journey from its early work in 3D-printed bone scaffolds to its ambitious new focus: growing simplified, functional “mini-livers” capable of keeping patients alive while a damaged liver recovers or while they wait for a transplant. CEO Caralynn Nowinski Collens describes their FDA-cleared bone-regeneration product as an important stepping stone — a validation of their technology and regulatory approach, even if it wasn’t commercially fast enough to compete with traditional bone grafts.
That early experience set the stage for a breakthrough. Dimension’s proprietary BioNidum scaffold, made from the widely used biomaterial PLGA, enables rapid blood-vessel growth — a key hurdle in tissue engineering. By engineering scaffolds with pores of varying sizes, the company created an environment where cells can integrate quickly without triggering the immune system to wall off the implant.
The opportunity is massive. In 2023 alone, more than 52,000 Americans died from liver disease or cirrhosis, and transplant shortages remain one of the biggest barriers to survival. Dimension aims to step into that gap by growing a small, temporary liver under the skin using billions of donor-derived or stem-cell-generated liver cells. In animal models, this approach has already boosted survival rates dramatically.
The article also spotlights Dimension’s roots in Northwestern University’s TEAM Lab, its diverse and women-led leadership team, and its strong investor backing — more than $20M raised to date, with a planned A2 round in 2026 targeting up to $50M. The company expects to begin human clinical trials in 2028.
As Collens notes, biotech is entering “a really interesting inflection point” where engineering and biology are converging in ways once thought unimaginable. With companies like Dimension Bio leading the charge, it’s clear Illinois is becoming a powerful hub for next-generation regenerative medicine.